SCHEMBL5689088

SCHEMBL5689088

CCCc1ccc(Oc2nc(Nc3ccc(OCCN4CCN(CCC)CC4)c(F)c3)ncc2C(=O)Nc2c(C)cccc2C)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LCK P06239 6/20 0.48
TNK2 Q07912 3/20 0.48
BTK Q06187 3/20 0.48
JAK3 P52333 2/20 0.48
KDR P35968 5/20 0.44
SRC P12931 4/20 0.42
MAPK14 Q16539 2/20 0.42
SIK1 P57059 2/20 0.42
SIK2 Q9H0K1 2/20 0.42
SIK3 Q9Y2K2 2/20 0.42
MET P08581 8/20 0.41
EGFR P00533 1/20 0.40
ITK Q08881 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496477 0.97 LCK (0.48) LCKTNK2BTKJAK3KDR
SCHEMBL4508685 0.96 LCK (0.49) LCKTNK2BTKJAK3KDR
SCHEMBL4484610 0.95 LCK (0.48) LCKTNK2BTKJAK3KDR
SCHEMBL4496208 0.95 LCK (0.47) LCKTNK2BTKJAK3KDR
SCHEMBL4497229 0.94 LCK (0.46) LCKTNK2BTKJAK3KDR
SCHEMBL4509376 0.94 LCK (0.55) LCKTNK2BTKJAK3KDR
SCHEMBL4495350 0.94 BTK (0.48) LCKTNK2BTKJAK3KDR
SCHEMBL4483801 0.94 LCK (0.49) LCKTNK2BTKJAK3KDR
SCHEMBL5686829 0.93 LCK (0.47) LCKTNK2BTKJAK3KDR
SCHEMBL4508549 0.93 TNK2 (0.49) LCKTNK2BTKJAK3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed